Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
ARIA [NASD]
Ariad Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.35 Insider Own1.94% Shs Outstand184.69M Perf Week-3.54%
Market Cap3.07B Forward P/E- EPS next Y-1.26 Insider Trans8.81% Shs Float179.37M Perf Month-11.12%
Income-229.65M PEG- EPS next Q-0.40 Inst Own84.21% Short Float7.10% Perf Quarter-20.93%
Sales6.94M P/S442.30 EPS this Y-43.39% Inst Trans15.25% Short Ratio4.26 Perf Half Y-16.19%
Book/sh1.97 P/B8.44 EPS next Y24.60% ROA-60.73% Target Price27.95 Perf Year-5.14%
Cash/sh2.16 P/C7.71 EPS next 5Y10.00% ROE-73.93% 52W Range15.13 - 25.40 Perf YTD-13.35%
Dividend- P/FCF- EPS past 5Y0.00% ROI-68.17% 52W High-34.57% Beta1.23
Dividend %- Quick Ratio7.74 Sales past 5Y-31.06% Gross Margin- 52W Low9.85% ATR0.72
Employees300 Current Ratio7.79 Sales Q/Q7880.25% Oper. Margin-3308.28% RSI (14)41.15 Volatility5.10% 4.10%
OptionableYes Debt/Eq0.08 EPS Q/Q-4.31% Profit Margin-3308.57% Rel Volume0.78 Prev Close16.67
ShortableYes LT Debt/Eq0.08 EarningsMay 07 BMO Payout- Avg Volume2.99M Price16.62
Recom1.70 SMA20-4.66% SMA50-9.76% SMA200-19.10% Volume2,357,500 Change-0.30%
26-Feb-13Reiterated Barclays Overweight $30 → $29
03-Jan-13Reiterated UBS Buy $29 → $26
23-Oct-12Downgrade Oppenheimer Outperform → Perform $20 → $23
01-Oct-12Reiterated Summer Street Research Buy $21 → $34
01-Oct-12Reiterated Brean Murray Buy $19 → $35
18-Sep-12Reiterated Maxim Group Buy $24 → $28
06-Sep-12Reiterated Stifel Nicolaus Buy $20 → $24
31-Jul-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $26
30-Jul-12Initiated William Blair Outperform
14-May-12Reiterated Summer Street Research Buy $16 → $21
12-Apr-12Initiated UBS Buy $20
15-Mar-12Initiated Stifel Nicolaus Buy $19
14-Feb-12Initiated RBC Capital Mkts Outperform $20
19-Jan-12Initiated Maxim Group Buy $20
27-Dec-11Reiterated Rodman & Renshaw Mkt Perform $15 → $18
09-Dec-11Initiated Barclays Capital Overweight $19
14-Oct-11Initiated Rodman & Renshaw Mkt Outperform $15
02-Aug-11Reiterated Brean Murray Buy $11 → $15
19-Jan-11Reiterated Brean Murray Buy $5 → $9
05-May-10Upgrade Brean Murray Hold → Buy $5
20-May-13 03:56PM  ARIA July Options Begin Trading at Forbes
01:50PM  Ariad Pharmaceuticals Inc. Presents at UBS Global Healthcare Conference, May-20-2013 08:30 AM at Seeking Alpha
19-May-13 06:30PM  Tackling Cancer: Leukemia's Biggest Current and Upcoming Players at Motley Fool
01:11PM  Whats Moving These Biotech Stocks? at Motley Fool
17-May-13 01:37PM  Analysts: Teslas Capital Efforts Are Beneficial and 3 More Research Notes to Read at Wall St. Cheat Sheet
01:04PM  ARIAD PHARMACEUTICALS INC Financials EDGAR Online Financials
16-May-13 02:05PM  3 Companies That Put the "Tech" in "Biotech" at Motley Fool
01:07PM  BlackBerry Overtaken By Windows Phone and 2 Other Hot Stocks to Watch at Wall St. Cheat Sheet
12:04PM  Ariad Stock Falls On Unusually High Volume (ARIA) at TheStreet
15-May-13 06:22PM  InPlay: Ariad Pharm announces data presentations and webcost of investor briefing at the 2013 ASCO Annual Meeting Briefing.com -5.10%
06:04PM  ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting Business Wire
06:00PM  10 ASCO '13 Abstracts You Can Read Right Now at TheStreet
05:59PM  New cancer tools allow patients to reconsider chemo at Reuters
14-May-13 10:45PM  ARIAD Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
02:30PM  2 Biotech Companies With Strong Product Launches To Monitor at Seeking Alpha
13-May-13 07:35AM  ARIAD to Present at UBS Global Healthcare Conference Business Wire +5.58%
10-May-13 09:33AM  ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09-May-13 03:46AM  Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector at Seeking Alpha
08-May-13 10:15AM  Ariad Posts Wider Y/Y Loss Zacks
07-May-13 06:54PM  Does Ariad's Leukemia Drug Have Hidden Potential? at Motley Fool
03:01PM  Ariad Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
02:10PM  Fords UK Sales Spike, Baxters Phase III Falls Short, and 3 Other Hot Stocks at Wall St. Cheat Sheet
12:06PM  Ariad reports $6.4M in 1Q sales of leukemia pill AP
09:28AM  Ariad Pharmaceuticals Earnings: Heres Why Investors Like These Results at Wall St. Cheat Sheet
08:30AM  ARIAD Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
08:15AM  ARIAD Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
07:37AM  InPlay: Ariad Pharm reports EPS in-line, beats on revs Briefing.com
07:35AM  ARIAD Reports First Quarter 2013 Financial Results and Development Progress Business Wire
07:07AM  Q1 2013 ARIAD Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
01:01AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
06-May-13 07:35AM  ARIAD to Present at Bank of America Merrill Lynch Healthcare Conference Business Wire
01-May-13 11:00AM  Invest In The War On Cancer With These Stocks The StreetAuthority Network
11:00AM  Invest In The War On Cancer With These Stocks StreetAuthority Network
11:00AM  Invest In The War On Cancer With These Stocks
11:00AM  Fight Cancer, Save Lives With These Stocks The StreetAuthority Network
30-Apr-13 11:42AM  These 3 Biotech Stocks Look Interesting at Motley Fool
29-Apr-13 11:46AM  Snatch ARIA 8.0% Lower Than Its Secondary? at Forbes
26-Apr-13 01:02PM  Hepatitis C Space an Opportunity with the Potential for an Upside Surprise, According to Expert Analyst David Ferreiro Wall Street Transcript
11:50AM  William A. Hartman, President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI), Interviews with The Wall Street Transcript Wall Street Transcript
12:01AM  Cancer Therapy Cost Too High for Patients, Doctors Say at Bloomberg
25-Apr-13 03:27PM  Cancer Therapies Cost Too High for Patients, Doctors Say at Bloomberg
23-Apr-13 07:35AM  ARIAD to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013 Business Wire
22-Apr-13 10:24AM  Want to Invest in Biotech? Think Like a Venture Capitalist at Motley Fool
18-Apr-13 04:23PM  SAC Capital Advisors likes this pharma stock at MarketWatch
17-Apr-13 07:44AM  [video] R&D For Your Portfolio: 3 Stocks in 3 Sectors at CNBC
16-Apr-13 07:55AM  AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential at Seeking Alpha
14-Apr-13 03:44PM  2 Oncology Biotechs For The Future at Seeking Alpha
12-Apr-13 05:20PM  Ariad Presents Data on AP26113 Zacks
11-Apr-13 04:18AM  Trader sees limited downside in Ariad optionMONSTER
03:55AM  Trader sees limited downside in Ariad optionMONSTER
03:23AM  Trader sees limited downside in Ariad optionMONSTER
10-Apr-13 04:10PM  More Data on Ariad's Iclusig Zacks
03:38PM  Short Interest In ARIAD Pharmaceuticals Drops 11.4% at Forbes
08:00AM  InPlay: Ariad Pharm presents new preclinical data showing AP26113 inhibits clinically relevant mutants of ALK and ROS1 Briefing.com
08:00AM  ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically Relevant Mutants of ALK and ROS1 Business Wire
09-Apr-13 05:17PM  Pre-Clinical Data on Ariad's Iclusig Zacks
08:02AM  ARIAD to present preclinical data on ponatinib theflyonthewall.com
08:01AM  InPlay: ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors Briefing.com
08:00AM  ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors Business Wire
04:16AM  Ariad Pharma trader won't jump ship optionMONSTER
03:23AM  Ariad Pharma trader won't jump ship optionMONSTER
08-Apr-13 02:09PM  ABC Loses Ratings War and 4 Other Hot Stocks at Wall St. Cheat Sheet
07:37AM  ARIAD presents new preclinical data on ponatinib at theflyonthewall.com
07:35AM  InPlay: Ariad Pharm presents new preclinical data showing Ponatinib is a potent inhibitor of RET and FGFR, two oncogenic drivers of non-small cell lung cancer Briefing.com
07:35AM  ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer Business Wire
12:10AM  Can Bristol-Myers Squibb Compete In Immuno-Oncology? at Seeking Alpha
05-Apr-13 05:18PM  R&D and Iclusig Update from Ariad Zacks
11:13AM  A Quick Response To Ariad's Conference Call at Seeking Alpha
07:55AM  Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech at TheStreet
04-Apr-13 07:17PM  Concerns Swirl Over Critical Drug Launch at Motley Fool
02:31PM  Ariad says 325 patients treated with leukemia drug AP
02:00PM  Ariad Pharmaceuticals Inc. - Special Call at Seeking Alpha
10:09AM  Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine at TheStreet
09:51AM  Apple Makes Amends With China and 4 Other Hot Stocks at Wall St. Cheat Sheet
07:44AM  ARIAD updates R&D and commercial progress for Iclusig and AP26113 theflyonthewall.com
07:37AM  InPlay: Ariad Pharm provides update on progress being made in R&D and commercial initiatives; more than 325 patients in U.S. now on Iclusig (ponatinib); Phase 2 cohorts of AP26113 on track to begin 2Q 2013 Briefing.com
07:35AM  ARIAD Provides Update on Important Progress Being Made in R&D and Commercial Initiatives Business Wire
03-Apr-13 11:01PM  CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET Business Wire
06:48PM  ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET Business Wire
02:24PM  Ariad Stock Falls On Unusually High Volume (ARIA) at TheStreet
01:43PM  The Survey Says: Ariad's Leukemia Drug Is Toxic at TheStreet
02-Apr-13 07:35AM  ARIAD Announces Support of Patients with Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund Business Wire
01-Apr-13 01:37PM  3 Under-the-Radar Tech Stocks: Top Portfolio Manager at CNBC
12:26PM  [video] 3 Under-the-Radar Tech Stocks: Pro at CNBC
29-Mar-13 06:30PM  Is IBM's Watson Really a Big Deal? at Motley Fool
28-Mar-13 08:34PM  Here's What This 1,022% Gainer Has Been Buying at Motley Fool
05:01PM  Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day at TheStreet
11:04AM  3 Reasons Investors Are Scared of Biotech Stocks at Motley Fool
08:48AM  New Stock Coverage: Everything's Rosy at Madison Square Garden at Minyanville
27-Mar-13 05:04PM  ARIAD Pharmaceuticals Larger Than S&P 500 Component Dean Foods at Forbes
12:52PM  Ariad Pharma Falls On Weak Leukemia Drug Prescriptions at TheStreet
09:57AM  Analysts: Apple Will Be Hurt by Slow Sales and 4 New Opinions Investors Must Know About at Wall St. Cheat Sheet
26-Mar-13 03:15PM  A Silver Lining in a Sea of Red at Motley Fool
03:00PM  U.S. Stock Options With Biggest Changes in Implied Volatility at Bloomberg
25-Mar-13 05:38PM  CHMP Positive on Ariad's Iclusig Zacks -5.37%
04:24PM  Ariad Stock Falls On Unusually High Volume (ARIA) at TheStreet
10:06AM  5 Stocks That Fell Every Day Last Week at Motley Fool
09:51AM  Macys Chief Merchandising Officer Sells 32K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
09:31AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
09:30AM  Weyerhaeuser Chief Accounting Officer Sells More Than 11K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERGER HARVEY J M DChairman & CEOMay 15Sale18.2237,098675,9701,516,837May 16 04:38 PM
BERGER HARVEY J M DChairman & CEOMay 15Sale18.142,70048,98316,657May 16 04:38 PM
BERGER HARVEY J M DChairman & CEOMay 14Sale18.0150,000900,2951,553,935May 16 04:38 PM
BERGER HARVEY J M DChairman & CEOMay 14Sale18.002,70048,60019,357May 16 04:38 PM
BERGER HARVEY J M DChairman & CEOApr 17Sale18.01100,0001,800,5901,667,521Apr 22 05:07 PM
BERGER HARVEY J M DChairman & CEOApr 17Sale18.005,40097,20122,057Apr 22 05:07 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerApr 02Sale18.052,40043,322208,898Apr 03 04:47 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityApr 02Sale18.052,40043,327117,871Apr 03 04:47 PM
FITZGERALD EDWARD MExecutive VP, CFOApr 02Sale18.045,20093,813199,355Apr 03 04:50 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsApr 02Sale18.042,40043,29557,682Apr 03 04:52 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 02Sale18.046,500117,245363,705Apr 03 04:53 PM
Cantor Maria ESVP, Corporate AffairsApr 02Sale18.044,25076,66562,275Apr 03 04:55 PM
Haluska FrankSVP, Clinical R&D, CMOApr 02Sale18.043,40061,33973,907Apr 03 04:57 PM
Keane Raymond TSVP General Counsel & CCOApr 02Sale18.052,58346,62554,096Apr 03 04:58 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerApr 01Option Exercise0.006,0000211,298Apr 03 04:47 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityApr 01Option Exercise0.006,0000120,271Apr 03 04:47 PM
BERGER HARVEY J M DChairman & CEOApr 01Option Exercise0.0041,66601,787,209Apr 03 04:51 PM
FITZGERALD EDWARD MExecutive VP, CFOApr 01Option Exercise0.0013,0000204,555Apr 03 04:50 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsApr 01Option Exercise0.006,000060,082Apr 03 04:52 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 01Option Exercise0.0013,0000370,205Apr 03 04:53 PM
Cantor Maria ESVP, Corporate AffairsApr 01Option Exercise0.008,500066,525Apr 03 04:55 PM
Haluska FrankSVP, Clinical R&D, CMOApr 01Option Exercise0.008,500077,307Apr 03 04:57 PM
Keane Raymond TSVP General Counsel & CCOApr 01Option Exercise0.005,166056,679Apr 03 04:58 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 26Sale18.7512,933242,492191,555Mar 26 04:57 PM
Keane Raymond TSVP General Counsel & CCOMar 25Sale18.8713,167248,48251,513Mar 26 04:40 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsMar 25Sale18.878,133153,48254,082Mar 26 04:38 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerMar 25Sale18.8710,533198,807205,298Mar 26 04:36 PM
Haluska FrankSVP, Clinical R&D, CMOMar 25Sale18.885,333100,67268,807Mar 26 04:36 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 25Sale18.8719,167361,766357,205Mar 26 04:34 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 25Sale18.8712,933244,079114,271Mar 26 04:32 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 22Option Exercise0.0032,3330204,488Mar 26 04:57 PM
Keane Raymond TSVP General Counsel & CCOMar 22Option Exercise0.0026,333064,680Mar 26 04:40 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsMar 22Option Exercise0.0020,333062,215Mar 26 04:38 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerMar 22Option Exercise0.0026,3330215,831Mar 26 04:36 PM
Haluska FrankSVP, Clinical R&D, CMOMar 22Option Exercise0.0013,333074,140Mar 26 04:36 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 22Option Exercise0.0038,3330376,372Mar 26 04:34 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 22Option Exercise0.0032,3330127,204Mar 26 04:32 PM
Cantor Maria ESVP, Corporate AffairsMar 22Option Exercise0.0018,000063,902Mar 26 04:32 PM
BERGER HARVEY J M DChairman & CEOMar 22Option Exercise0.0097,66701,791,691Mar 26 04:30 PM
Duvall Martin JSVP, Commercial OperationsMar 22Sale19.5357611,2492,854Mar 22 06:51 PM
Keane Raymond TSVP General Counsel & CCOMar 22Sale19.462,33445,42338,347Mar 22 06:38 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsMar 22Sale19.462,40046,69841,882Mar 22 06:31 PM
Haluska FrankSVP, Clinical R&D, CMOMar 22Sale19.462,40046,69460,807Mar 22 06:29 PM
Cantor Maria ESVP, Corporate AffairsMar 22Sale19.453,66771,33542,235Mar 22 05:14 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 22Sale19.462,40046,69494,871Mar 22 06:09 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerMar 22Sale19.461,60031,135189,498Mar 22 06:05 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 22Sale19.466,667129,718338,039Mar 22 06:03 PM
BERGER HARVEY J M DChairman & CEOMar 20Option Exercise0.0034,00001,710,089Mar 22 07:07 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 20Option Exercise0.008,3340174,877Mar 22 07:02 PM
Duvall Martin JSVP, Commercial OperationsMar 20Option Exercise0.001,66703,430Mar 22 06:51 PM
Keane Raymond TSVP General Counsel & CCOMar 20Option Exercise0.004,667040,681Mar 22 06:38 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsMar 20Option Exercise0.006,000044,282Mar 22 06:31 PM
Cantor Maria ESVP, Corporate AffairsMar 20Option Exercise0.007,334045,902Mar 22 05:14 PM
Haluska FrankSVP, Clinical R&D, CMOMar 20Option Exercise0.006,000063,207Mar 22 06:29 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 20Option Exercise0.006,000097,271Mar 22 06:09 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerMar 20Option Exercise0.004,0000191,098Mar 22 06:05 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 20Option Exercise0.0013,3340344,706Mar 22 06:03 PM
BERGER HARVEY J M DChairman & CEOMar 13Sale22.072,70059,58727,457Mar 14 04:33 PM
BERGER HARVEY J M DChairman & CEOMar 13Sale22.0650,0001,102,9901,676,089Mar 14 04:33 PM
Cantor Maria ESVP, Corporate AffairsMar 12Sale22.002,10546,31038,568Mar 13 04:35 PM
BERGER HARVEY J M DChairman & CEOMar 12Sale22.042,70059,51630,157Mar 14 04:33 PM
BERGER HARVEY J M DChairman & CEOMar 12Sale22.0450,0001,101,7551,726,089Mar 14 04:33 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 04Sale21.009,838206,598331,372Mar 05 04:44 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJan 15Option Exercise5.0557,939292,414341,210Jan 17 04:44 PM
FITZGERALD EDWARD MExecutive VP, CFOJan 02Sale20.0825,000501,890166,543Jan 03 04:30 PM
LAVIDAS ATHANESEDirectorDec 21Sale20.3110,500213,20980,131Dec 27 04:45 PM
CLACKSON TIMOTHY PPresident, R&D, CSODec 20Option Exercise5.2327,000141,210282,940Dec 21 04:28 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityDec 18Option Exercise0.009,000095,029Dec 20 04:46 PM
Cantor Maria ESVP, Corporate AffairsDec 18Option Exercise0.0012,750045,997Dec 20 04:44 PM
CLACKSON TIMOTHY PPresident, R&D, CSODec 18Option Exercise0.0019,5000264,082Dec 20 04:41 PM
FITZGERALD EDWARD MExecutive VP, CFODec 18Option Exercise0.0019,5000199,499Dec 20 04:39 PM
Haluska FrankSVP, Clinical R&D, CMODec 18Option Exercise0.0012,750062,531Dec 20 04:37 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsDec 18Option Exercise0.009,000042,040Dec 20 04:35 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerDec 18Option Exercise0.009,0000190,856Dec 20 04:30 PM
BERGER HARVEY J M DChairman & CEODec 18Option Exercise0.0062,50002,252,183Dec 20 04:27 PM
Keane Raymond TSVP General Counsel & CCODec 18Option Exercise0.007,750039,250Dec 20 04:24 PM
LAMARCHE JAY RDirectorOct 01Sale24.9910,000249,932400,705Oct 03 04:02 PM
FITZGERALD EDWARD MExecutive VP, CFOOct 01Sale24.1725,000604,188179,767Oct 02 04:11 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 19Option Exercise5.2311,37559,491201,231Sep 20 12:32 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 19Sale24.007,500180,00085,519Sep 20 12:34 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 19Sale24.0019,375465,000181,856Sep 20 12:32 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 11Option Exercise5.2311,37559,491201,231Sep 12 04:02 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 11Option Exercise5.2311,37559,491201,231Sep 12 04:05 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 11Option Exercise1.307,5009,75093,019Sep 12 04:10 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 11Sale23.007,500172,50085,519Sep 12 04:10 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 11Sale23.0019,375445,625189,856Sep 12 04:05 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 11Sale23.0019,375445,625189,856Sep 12 04:02 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 06Option Exercise5.2311,37559,491205,700Sep 07 04:16 PM
Keane Raymond TSVP General Counsel & CCOSep 06Option Exercise2.3910,00023,90041,500Sep 07 04:18 PM
LAMARCHE JAY RDirectorSep 06Option Exercise2.6615,00039,900525,205Sep 07 04:55 PM
Keane Raymond TSVP General Counsel & CCOSep 06Sale22.0010,000220,00031,500Sep 07 04:18 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 06Sale22.0019,375426,250197,856Sep 07 04:16 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 04Option Exercise5.238,05042,102221,906Sep 05 04:15 PM
Keane Raymond TSVP General Counsel & CCOSep 04Sale21.007,780163,38031,500Sep 05 04:18 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerSep 04Sale21.0016,050337,050205,856Sep 05 04:15 PM
CLACKSON TIMOTHY PPresident, R&D, CSOAug 30Option Exercise3.2510,00132,503244,170Sep 04 04:08 PM
CLACKSON TIMOTHY PPresident, R&D, CSOAug 15Option Exercise7.5636,843278,533271,012Aug 16 04:07 PM
Keane Raymond TSVP General Counsel & CCOAug 15Option Exercise2.3910,00023,90049,280Aug 16 04:09 PM
LAMARCHE JAY RDirectorAug 15Sale20.0020,000400,032518,893Aug 16 04:10 PM
Keane Raymond TSVP General Counsel & CCOAug 15Sale20.0010,000200,00039,280Aug 16 04:09 PM
open in yahoo | open in reuters | open in google